Neuroleptic malignant syndrome (NMS) is characterised by the impairment of consciousness, high fever, rigidity and autonomic instability. Although originally described in patients taking neuroleptic drugs, this syndrome may also occur in patients with Parkinson’s disease (PD) during withdrawal or reduction of levodopa therapy or other dopaminergic drug therapy and is called malignant syndrome (MS) or neuroleptic-like syndrome.
This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.
